Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity

Cancer Science

Volumn 99, Issue 5, 2008, Pages 1034-1039

  Woo, Sun Je ^a   Kim, Chang Hyun ^a   Park, Mi Young ^a   Kim, Hye Sung ^a   Sohn, Hyun Jung ^b   Park, Jung Sun ^a   Kim, Hyung Jin ^a   Oh, Seong Taek ^a   Kim, Tai Gyu ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; T LYMPHOCYTE ANTIGEN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; APOPTOSIS REGULATORY PROTEIN; CANCER VACCINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; HIV TAT SURVIVIN (T34A) PROTEIN; HIV-TAT-SURVIVIN (T34A) PROTEIN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INNATE IMMUNITY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TH1 CELL; TUMOR IMMUNITY; TUMOR MODEL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 43649097986     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00760.x     Document Type: Article

References (34)

1. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-54.
2. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
3. Sparwasser T, Vabulas RM, Villmow B et al. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000; 30: 3591-7.
4. Bohle B, Jahn-Schmid B, Maurer D et al. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999; 29: 53.
5. Davis HL, Weeranta R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160: 870-6.
6. Warren TL, Bhatia SK, Acosta AM et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000; 165: 6244-51.
7. Chaung HC. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 2006; 6: 1586-96.
8. Spies B, Hochrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003; 171: 5908-12.
9. Heit A, Huster KM, Schmitz F et al. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004; 172: 1501-7.
10. + T cells. J Immunol 2003; 171: 5198-207.
11. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.
12. Kim DT, Mitchell DJ, Brockstedt DG et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159: 1666-8.
13. Riedl P, Reimann J, Schirmbeck R. Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med 2004; 82: 144-52.
14. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Laboratory Anal 1991; 5: 344-66.
15. Oh ST, Kim CH, Park MY et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006; 24: 2860-8.
16. Aldrich WA, Ren C, White AF et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2006; 13: 29-39.
17. Hörig H, Medina FA, Conkright WA et al. Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert Rev Mol Med 2000; 2: 1-24.
18. Cho HI, Kim HJ, Oh ST et al. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003; 22: 224-36.
19. Park MY, Kim CH, Sohn HJ et al. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine 2007; 25: 7322-30.
20. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
21. Kim CH, Hong MJ, Park SD et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006; 55: 1309-19.
22. Finkelman FD, Holmes J, Katona IM et al. Lymphokine control of in vivo immuno-globulin isotype selection. Annu Rev Immunol 1990; 8: 303-33.
23. Shen Y, Ichino M, Nakazawa M et al. CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol 2005; 124: 1141-8.
24. Liu N, Ohnishi N, Ni L, Akira S et al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4: 687-93.
25. Kim TG, Kim CH, Won EH et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16, E7-associated animal tumour model. Immunology 2004; 112: 117-25.
26. Schneeberger A, Wagner C, Zemann A et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004; 123: 371-9.
27. Luhrs P, Schmidt W, Kutil R et al. Induction of specific immune responses by polycation-based vaccines. J Immunol 2002; 169: 5217-26.
28. Mattner F, Fleitmann JK, Lingnau K et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 2002; 62: 1477-80.
29. Lingnau K, Egyed A, Schellack C et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 2002; 20: 3498-508.
30. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005; 57: 559-77.
31. Morris MC, Depollier J, Mery J et al. peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
32. Snyder EL, Dowdy SF. Protein/peptide transduction domains: Potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 2001; 3: 147-52.
33. Mitsui H, Inozume T, Kitamura R et al. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 2006; 126: 1804-12.
34. + T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006; 63: 35-41.